» Articles » PMID: 31198410

A Brief Review on Resistance to P2Y Receptor Antagonism in Coronary Artery Disease

Overview
Journal Thromb J
Publisher Biomed Central
Date 2019 Jun 15
PMID 31198410
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Platelet inhibition is important for patients with coronary artery disease. When dual antiplatelet therapy (DAPT) is required, a P2Y-antagonist is usually recommended in addition to standard aspirin therapy. The most used P2Y-antagonists are clopidogrel, prasugrel and ticagrelor. Despite DAPT, some patients experience adverse cardiovascular events, and insufficient platelet inhibition has been suggested as a possible cause. In the present review we have performed a literature search on prevalence, mechanisms and clinical implications of resistance to P2Y inhibitors.

Methods: The PubMed database was searched for relevant papers and 11 meta-analyses were included. P2Y resistance is measured by stimulating platelets with ADP ex vivo and the most used assays are vasodilator stimulated phosphoprotein (VASP), Multiplate, VerifyNow (VN) and light transmission aggregometry (LTA).

Discussion/conclusion: The frequency of high platelet reactivity (HPR) during clopidogrel therapy is predicted to be 30%. Genetic polymorphisms and drug-drug interactions are discussed to explain a significant part of this inter-individual variation. HPR during prasugrel and ticagrelor treatment is estimated to be 3-15% and 0-3%, respectively. This lower frequency is explained by less complicated and more efficient generation of the active metabolite compared to clopidogrel. Meta-analyses do show a positive effect of adjusting standard clopidogrel treatment based on platelet function testing. Despite this, personalized therapy is not recommended because no large-scale RCT have shown any clinical benefit. For patients on prasugrel and ticagrelor, platelet function testing is not recommended due to low occurrence of HPR.

Citing Articles

High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease.

Nolfi-Donegan D, Annarapu G, St Croix C, Calderon M, Hillery C, Shiva S JCI Insight. 2024; 9(5).

PMID: 38456510 PMC: 10972595. DOI: 10.1172/jci.insight.174575.


Prasugrel Single Antiplatelet Therapy versus Aspirin and Clopidogrel Dual Antiplatelet Therapy for Flow Diverter Treatment for Cerebral Aneurysms: A Retrospective Multicenter Study.

Hohenstatt S, Saatci I, Jesser J, Cekirge H, Kocer N, Islak C AJNR Am J Neuroradiol. 2024; 45(5):592-598.

PMID: 38453414 PMC: 11288545. DOI: 10.3174/ajnr.A8163.


Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review.

Tang K, Banerjee S, Tang G, Patel P, Frangieh A Interv Cardiol. 2024; 18:e31.

PMID: 38213748 PMC: 10782423. DOI: 10.15420/icr.2023.19.


A proposed modern standardized technical approach for symptomatic chronic carotid total occlusion management.

Radu R, Cagnazzo F, Ter Schiphorst A, Machi P, Dargazanli C, Lefevre P Interv Neuroradiol. 2024; :15910199231224006.

PMID: 38166519 PMC: 11569722. DOI: 10.1177/15910199231224006.


The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy.

Zhao Z, Dong S, Sun T, Han K, Huang X, Ma M Front Cardiovasc Med. 2023; 10:1115142.

PMID: 37304959 PMC: 10250738. DOI: 10.3389/fcvm.2023.1115142.


References
1.
Farid N, Payne C, Small D, Winters K, Ernest 2nd C, Brandt J . Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007; 81(5):735-41. DOI: 10.1038/sj.clpt.6100139. View

2.
Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20):2001-15. DOI: 10.1056/NEJMoa0706482. View

3.
Wallentin L, Varenhorst C, James S, Erlinge D, Braun O, Jakubowski J . Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2007; 29(1):21-30. DOI: 10.1093/eurheartj/ehm545. View

4.
Wiviott S, Trenk D, Frelinger A, ODonoghue M, Neumann F, Michelson A . Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in.... Circulation. 2007; 116(25):2923-32. DOI: 10.1161/CIRCULATIONAHA.107.740324. View

5.
Trenk D, Hochholzer W, Frundi D, Stratz C, Valina C, Bestehorn H . Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost. 2008; 99(1):174-81. DOI: 10.1160/TH07-08-0503. View